RE
PACB icon

RBC Europe’s Pacific Biosciences PACB Stock Holding History

RBC Europe’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-184
Closed -$4.7K – 984
2021
Q3 		$4.7K Hold
184
– – ﹤0.01% 1051
2021
Q2 		$6.43K Hold
184
– – ﹤0.01% 1025
2021
Q1 		$6.13K Buy
+184
New +$6.44K ﹤0.01% 985
2017
Q4 		– Sell
-1,500
Closed -$7.88K – 1154
2017
Q3 		$7.88K Buy
+1,500
New +$6.45K ﹤0.01% 886

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RBC Europe's PACB Position: Q4 2021 in Review

RBC Europe sold out of Pacific Biosciences (PACB) in Q4 2021, closing a stake of 184 shares — an estimated $4.7K sold.

RBC Europe first reported a position in PACB in Q3 2017 and held it in 4 quarters. The position peaked at $7.88K in Q3 2017. 256 funds tracked by Wall St. Rank hold PACB as of Q4 2021.

  • RBC Europe reported no remaining Pacific Biosciences position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 184 Pacific Biosciences shares in Q4 2021, an estimated $4.7K.
  • RBC Europe first reported a position in Pacific Biosciences in Q3 2017 and held it in 4 quarters.
  • RBC Europe's Pacific Biosciences position peaked at $7.88K in Q3 2017.
  • 256 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.